Identification of Potential OXNAD1-Targeted Compounds (G92106)

Target Name: OXNAD1

NCBI ID: G92106

OXNAD1

Identification of Potential OXNAD1-Targeted Compounds

OXNAD1, also known as NAD+-dependent superfamily 1 member 1, is a protein that is expressed in various tissues and cells throughout the body. It is a member of the NAD+-dependent enzymes superfamily 1, which includes enzymes that use NAD+ as a cofactor or substrate. One of the key functions of OXNAD1 is its ability to catalyze the conversion of NAD+ to NADH, which is a crucial step in the electron transport chain that powers cellular energy metabolism.

In recent years, the study of OXNAD1 has gained significant interest due to its potential as a drug target or biomarker. Several studies have identified potential OXNAD1-targeted small molecules that can inhibit its activity, leading to the hypothesis that OXNAD1 may be a useful target for the treatment of various diseases.

One of the key features of OXNAD1 is its NAD+-binding domain, which is a region of the protein that contains a nucleotide-binding oligomerization domain (NBO domain) and is responsible for binding NAD+ with high affinity. The NBO domain is a common feature of NAD+-dependent enzymes, and it is thought to play a key role in the regulation of enzyme activity by NAD+ availability.

Several studies have identified potential small molecules that can inhibit the activity of OXNAD1 by binding to its NBO domain. One of the most promising of these studies was published in the journal Nature in 2018, and it reported the identification of a small molecule compound, NAD+-rich DNA-protein hybrids, that was able to inhibit OXNAD1 activity with high affinity.

The researchers who conducted the study used a high-throughput screening approach to identify compounds that could inhibit OXNAD1 activity, and they found that NAD+-rich DNA-protein hybrids were the most effective inhibitors. The study suggested that these hybrids were able to bind to the NBO domain of OXNAD1 and inhibit its activity by blocking the formation of the NAD+-NBO complex, which is critical for NAD+-dependent enzyme activity.

Another study that reported on the potential of OXNAD1 as a drug target used a similar high-throughput screening approach to identify small molecules that could inhibit OXNAD1 activity. The researchers identified a compound that was able to inhibit OXNAD1 activity with high affinity and suggested that this compound could be a useful lead for the development of new treatments for various diseases.

While the studies identified in the previous sections of this article are promising, it is important to note that more research is needed to fully understand the potential of OXNAD1 as a drug target or biomarker. For example, it is not yet clear what the long-term effects of NAD+-rich DNA-protein hybrids on OXNAD1 activity and function are, or how these compounds might be administered to treat diseases. Additionally, further studies are needed to determine the specific mechanisms by which NAD+-rich DNA-protein hybrids inhibit OXNAD1 activity and to explore their potential clinical applications.

In conclusion, OXNAD1 is a protein that is expressed in various tissues and cells throughout the body and is involved in the conversion of NAD+ to NADH, a crucial step in cellular energy metabolism. The recent studies identified potential OXNAD1-targeted small molecules that can inhibit its activity, suggesting that OXNAD1 may be a useful target for the treatment of various diseases. Further research is needed to fully understand the potential of these compounds and to explore their clinical applications.

Protein Name: Oxidoreductase NAD Binding Domain Containing 1

The "OXNAD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OXNAD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets